US2018298011A1PendingUtilityA1
Pyrazolo[1,5-a]pyrimidines for antiviral treatment
Est. expiryJun 24, 2030(~3.9 yrs left)· nominal 20-yr term from priority
Inventors:Kerim BabaogluConstantine G. BoojamraEugene J. EisenbergHon Chung HuiRichard L. MackmanJay P. ParrishMichael SangiOliver L. SaundersDustin SiegelDavid SperandioHai Yang
A61P 31/14A61P 31/12A61P 31/16A61P 11/00A61K 45/06C07F 9/65616C07D 487/04A61K 31/519C07D 519/00C07D 495/04A61K 31/55A61K 31/551A61K 31/5377A61K 31/675C07D 513/04
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
Claims
exact text as granted — not AI-modified1 - 38 . (canceled)
39 . A compound selected from the group consisting of:
or pharmaceutically acceptable salts and esters thereof.
40 . A compound selected from the group consisting of:
or a pharmaceutically acceptable salts and esters thereof.
41 . A method of treating a Pneumovirinae virus infection in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound of claim 39 or a pharmaceutically acceptable salt or ester thereof.
42 . A method of treating a Pneumovirinae virus infection in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound of claim 40 or a pharmaceutically acceptable salt or ester thereof.
43 . The method of claim 41 wherein the Pneumovirinae virus infection is caused by a respiratory syncytial virus.
44 . The method of claim 42 wherein the Pneumovirinae virus infection is caused by a respiratory syncytial virus.
45 . The method of claim 41 further comprising administering a therapeutically effective amount of at least one other therapeutic agent or composition thereof selected from the group consisting of ribavirin, palivizumab, motavizumab, RSV-IGIV MEDI-557, A-60444, MDT-637, BMS-433771, ALN-RSV0 and ALX-0171 or mixtures thereof.
46 . The method of claim 42 further comprising administering a therapeutically effective amount of at least one other therapeutic agent or composition thereof selected from the group consisting of ribavirin, palivizumab, motavizumab, RSV-IGIV MEDI-557, A-60444, MDT-637, BMS-433771, ALN-RSV0 and ALX-0171 or mixtures thereof.Join the waitlist — get patent alerts
Track US2018298011A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.